Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 202

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 202
---
: 

    External research and development 
    $4,355,449  
    $4,683,828 
  
    Internal personnel costs 
     2,895,648  
     2,937,879 
  
    Total research and development 
     7,251,097  
     7,621,707 
  
    General and administrative 
     8,114,654  
     8,756,767 
  
    Other income, net 
     (343,724) 
     (955,003)
  
    Net loss 
    $15,022,027  
    $15,423,471 

NOTE
10: SUBSEQUENT EVENTS

The
Company evaluated subsequent events from December 31, 2024, the date of these consolidated financial statements, through March 13, 2024,
which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the consolidated
financial statements for the year ended December 31, 2024. The Company concluded that no events have occurred that would require recognition
or disclosure in the consolidated financial statements, except for the January 2025 Offering that was completed on January 16, 2025,
as described in Note 6(e) and for the SEPA that was entered with Yorkville on February 12, 2025, as described in Note 6(f).

F-17

Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item
9A. Controls and Procedures. Disclosure Controls and Procedures.

Limitations
on Effectiveness of Controls and Procedures

In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply
judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation
of Disclosure Controls and Procedures

Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of December 31,
2024, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).
Based on that evaluation, our principal executive officer and principal financial officer